共 50 条
No Overt Clinical Immunodeficiency Despite Immune Biological Abnormalities in Patients With Constitutional Mismatch Repair Deficiency
被引:19
|作者:
Tesch, Victoria K.
[1
]
IJspeert, Hanna
[2
]
Raicht, Andrea
[1
]
Rueda, Daniel
[3
]
Dominguez-Pinilla, Nerea
[4
,5
]
Allende, Luis M.
[6
]
Colas, Chrystelle
[7
]
Rosenbaum, Thorsten
[8
]
Ilencikova, Denisa
[9
]
Baris, Hagit N.
[10
]
Nathrath, Michaela H. M.
[11
,12
]
Suerink, Manon
[13
]
Januszkiewicz-Lewandowska, Danuta
[14
]
Ragab, Iman
[15
]
Azizi, Amedeo A.
[16
]
Wenzel, Soeren S.
[17
]
Zschocke, Johannes
[17
]
Schwinger, Wolfgang
[1
]
Kloor, Matthias
[18
]
Blattmann, Claudia
[19
]
Brugieres, Laurence
[20
]
van der Burg, Mirjam
[2
]
Wimmer, Katharina
[17
]
Seidel, Markus G.
[1
]
机构:
[1] Med Univ, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Res Unit Pediat Hematol & Immunol, Graz, Austria
[2] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Rotterdam, Netherlands
[3] Univ Hosp Doce Octubre, Res Inst 1 12, Hereditary Canc Lab, Madrid, Spain
[4] Virgen Salud Hosp, Dept Pediat Hematol & Oncol, Toledo, Spain
[5] Univ Hosp Doce Octubre, Res Inst 1 12, Madrid, Spain
[6] Univ Hosp Doce Octubre, Res Inst 1 12, Dept Immunol, Madrid, Spain
[7] Curie Inst, Genet Dept, Paris, France
[8] Sana Kliniken Duisburg, Dept Pediat, Duisburg, Germany
[9] Comenius Univ, Dept Pediat, Bratislava, Slovakia
[10] Rambam Hlth Care Campus, Ruth & Bruce Rappaport Fac Med, Technion Israel Inst Technol, Genet Inst, Haifa, Israel
[11] Klinikum Kassel, Pediat Hematol & Oncol, Kassel, Germany
[12] Tech Univ Munich, Pediat Oncol Ctr, Dept Pediat, Munich, Germany
[13] Leiden Univ, Med Ctr, Dept Clin Genet, Leiden, Netherlands
[14] Poznan Univ Med Sci, Dept Pediat Oncol, Hematol & Transplantat, Poznan, Poland
[15] Ain Shams Univ, Dept Pediat, Hematol Oncol Unit, Fac Med, Cairo, Egypt
[16] Med Univ Vienna, Adolescent Med, Dept Pediat, Vienna, Austria
[17] Med Univ Innsbruck, Div Human Genet, Innsbruck, Austria
[18] Med Univ Heidelberg, Inst Pathol, Dept Appl Tumor Biol, Heidelberg, Germany
[19] Olgahospital Stuttgart, Dept Hematol Oncol & Immunol, Stuttgart, Germany
[20] Gustave Roussy Canc Campus, Dept Pediat & Adolescent Oncol, Villejuif, France
来源:
关键词:
primary immunodeficiency;
hyper-IgM syndrome;
DNA repair defect;
mismatch repair;
somatic hypermutation;
class-switch recombination;
IgA deficiency;
IgG subclass deficiency;
CLASS-SWITCH RECOMBINATION;
MEMORY B-CELLS;
EUROPEAN CONSORTIUM CARE;
MSH6;
MUTATIONS;
EARLY-ONSET;
HEMATOLOGICAL MALIGNANCY;
COMPOUND HETEROZYGOSITY;
SOMATIC HYPERMUTATION;
IMMUNOGLOBULIN;
REPERTOIRE;
D O I:
10.3389/fimmu.2018.01506
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Immunoglobulin class-switch recombination (CSR) and somatic hypermutations (SHMs) are prerequisites for antibody and immunoglobulin receptor maturation and adaptive immune diversity. The mismatch repair (MMR) machinery, consisting of homologs of MutS alpha, MutL alpha, and MutS beta (MSH2/MSH6, MLH1/PMS2, and MSH2/MSH3, respectively) and other proteins, is involved in CSR, primarily acting as a backup for nonhomologous end-joining repair of activation-induced cytidine deaminase-induced DNA mismatches and, furthermore, in addition to error-prone polymerases, in the repair of SHM-induced DNA breaks. A varying degree of antibody formation defect, from IgA or selective IgG subclass deficiency to common variable immunodeficiency and hyper-IgM syndrome, has been detected in a small number of patients with constitutional mismatch repair deficiency (CMMRD) due to biallelic loss-of-function mutations in one of the MMR genes (PMS2, MSH6, MLH1, or MSH2). To elucidate the clinical relevance of a presumed primary immunodeficiency (PID) in CMMRD, we systematically collected clinical history and laboratory data of a cohort of 15 consecutive, unrelated patients (10 not previously reported) with homozygous/compound heterozygous mutations in PMS2 (n = 8), MSH6 (n = 5), and MLH1 (n = 2), most of whom manifested with typical malignancies during childhood. Detailed descriptions of their genotypes, phenotypes, and family histories are provided. Importantly, none of the patients showed any clinical warning signs of PID (infections, immune dysregulation, inflammation, failure to thrive, etc.). Furthermore, we could not detect uniform or specific patterns of laboratory abnormalities. The concentration of IgM was increased in 3 out of 12, reduced in 3 out of 12, and normal in 6 out of 12 patients, while concentrations of IgG and IgG subclasses, except IgG4, and of IgA, and specific antibody formation were normal in most. Class-switched B memory cells were reduced in 5 out of 12 patients, and in 9 out of 12 also the CD38(hi)IgM(-)plasmablasts were reduced. Furthermore, results of next generation sequencing-based analyses of antigen-selected B-cell receptor rearrangements showed a significantly reduced frequency of SHM and an increased number of rearranged immunoglobulin heavy chain (IGH) transcripts that use IGHG3, IGHG1, and IGHA1 subclasses. T cell subsets and receptor repertoires were unaffected. Together, neither clinical nor routine immunological laboratory parameters were consistently suggestive of PID in these CMMRD patients, but previously shown abnormalities in SHM and rearranged heavy chain transcripts were confirmed.
引用
收藏
页数:16
相关论文